GlassScriptPhysician profile
George Lane Stankevych
NPI 1053312934
$1,959.61
in general payments reported to CMS, 2019-2025
24 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $93.30 · 2021: $380 · 2022: $274 · 2023: $250 · 2024: $140 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.41 | 2019-2024 | Liletta, Lo Loestrin Fe |
| Exeltis, USA INC. | $236.23 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $169.17 | 2019-2021 | |
| Biogen, INC. | $110.53 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $109.27 | 2021-2024 | Twirla |
| Amag Pharmaceuticals, INC. | $108.44 | 2019 | |
| Astellas Pharma US INC | $102.61 | 2023-2025 | Veozah |
| Avion Pharmaceuticals | $93.36 | 2019-2021 | |
| Aspira Women'S Health INC | $90.41 | 2022-2024 | Ova1 |
| Coopersurgical, INC. | $75.88 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $65.80 | 2019-2021 | |
| Hologic Sales and Service, LLC | $64.17 | 2021-2023 | Aptima |
| Exact Sciences Corporation | $54.24 | 2025 | The Cologuard Plus Collection Kit |
| Mayne Pharma Commercial LLC | $39.22 | 2023 | |
| Allergan, INC. | $29.07 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $22.66 | 2019 | |
| Octapharma USA, INC. | $21.06 | 2025 | Fibryga |
| Pfizer INC. | $20.23 | 2024 | |
| Duchesnay USA Incorporated | $18.70 | 2019 | |
| Scynexis, INC. | $17.83 | 2022 | |
| Millicent US INC | $15.91 | 2025 | Femlyv |
| Minerva Surgical, INC | $15.23 | 2022 | |
| Dysis Medical, INC. | $13.50 | 2019 | |
| Acessa Health INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Stankevych listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.